Improving the efficiency of fixed costs, including personnel expenses
First written in FY2017-Q1. 8 of 11 entries say "Advanced", first in FY2017. Latest entry: 2026-08-12.
The whole theme swung hardest in 2025: 2 of 13 companies on the "Worse" side.
11 other companies' latest entry also says "Advanced".
- 2026-08-12AdvancedEarnings
「However, in anticipation of the closure of the Kobe Research Institute, we advanced preparations to transfer and reallocate the functions of its genetically modified mouse business and large-animal pharmacology business, while working to reduce costs through more efficient business operations.」
The company implemented cost reductions through more efficient business operations while preparing to transfer and reallocate the functions of the Kobe Research Institute. - FY2026AdvancedAnnual report
「We also focused on reducing costs through delivery-date management for contracted studies and by reviewing our business operations.」
Cost reductions were specifically advanced through stronger delivery-date management for contracted studies and a review of business operations, contributing to a reduction in losses in the drug discovery support business. - FY2026-H1AdvancedAnnual report
「We also focused on reducing costs through delivery-date management for contracted studies and by reviewing our business operations.」
Cost reductions were specifically advanced through stronger delivery-date management for contracted studies and a review of business operations as part of efforts to improve fixed-cost efficiency and business operations. - FY2017AdvancedAnnual report
「Changes in the sales mix within the segment and more efficient work processes reduced the cost-of-sales ratio to 67.5% from 70.6% in the previous fiscal year. More efficient fixed costs, including personnel expenses, also reduced the SG&A-to-sales ratio to 25.8% from 27.2%.」
More efficient work processes and fixed costs improved both the cost-of-sales ratio and the SG&A-to-sales ratio, contributing to operating profit of ¥153.948 million. - FY2017-Q3RestatedAnnual report
「Against this backdrop, in the genomics business, the Group focused on orders using genome-editing technology (CRISPR/Cas9), which can shorten production times and further reduce costs for contract services for genetically modified mice, while working to improve the efficiency of fixed costs, including labour costs.」
We continue to improve the efficiency of fixed costs, including personnel expenses. - FY2017-Q2RestatedAnnual report
「In the genomics business, the Group focused on orders using genome-editing technology (CRISPR/Cas9), which can shorten production times and further reduce costs for contract services for genetically modified mice, while working to improve the efficiency of fixed costs, including labour costs.」
Improving the efficiency of fixed costs, including personnel expenses, continues to be cited. - FY2017-Q1First statedAnnual report
「On the cost front, we worked to improve the efficiency of fixed costs, including personnel expenses.」
Improving the efficiency of fixed costs, including personnel expenses, is newly stated as a cost initiative for the genomics business.